AgomAb Therapeutics N.V. American Depositary Shares
AgomAb Therapeutics N.V. American Depositary Shares
Your view on AGMB
Overview
What the company does, where it operates, and who runs it.
About AgomAb Therapeutics N.V. American Depositary Shares
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Tim Knotnerus
- Headquarters
- Posthoflei 1/6, Antwerp, VL, BE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Tim Knotnerus
- Headquarters
- Posthoflei 1/6, Antwerp, VL, BE
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist.
Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials.
Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF.
This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for AgomAb Therapeutics N.V. American Depositary Shares, and the rating behind it. AGMB last traded at $8.69; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for AgomAb Therapeutics N.V. American Depositary Shares. Starting points for AgomAb Therapeutics N.V. American Depositary Shares: EPS -$0.73, beta 1.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for AgomAb Therapeutics N.V. American Depositary Shares. AgomAb Therapeutics N.V. American Depositary Shares does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for AgomAb Therapeutics N.V. American Depositary Shares. Trailing twelve-month EPS for AgomAb Therapeutics N.V. American Depositary Shares stands at -$0.73. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for AgomAb Therapeutics N.V. American Depositary Shares. AgomAb Therapeutics N.V. American Depositary Shares has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
AgomAb Therapeutics N.V. American Depositary Shares valued side by side against its closest peers. AgomAb Therapeutics N.V. American Depositary Shares is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold AgomAb Therapeutics N.V. American Depositary Shares, and how their positions are changing. At a $428.0M market value, institutional positions materially move AgomAb Therapeutics N.V. American Depositary Shares's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by AgomAb Therapeutics N.V. American Depositary Shares executives and directors. Shares of AgomAb Therapeutics N.V. American Depositary Shares have traded between $8.75 and $17.82 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming AgomAb Therapeutics N.V. American Depositary Shares. AgomAb Therapeutics N.V. American Depositary Shares is a $428.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming AgomAb Therapeutics N.V. American Depositary Shares. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for AgomAb Therapeutics N.V. American Depositary Shares. Coverage tracks AgomAb Therapeutics N.V. American Depositary Shares within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.